glp-1 drugs and dementia Drug Fails to Quell Alzheimer's in Novo Nordisk Trials NEW STUDY: GLP-1 meds slash

You're feeling that in the brain, but the signals to feel that are coming from your gut

Obesity is a well-established major risk factor for metabolic disorders including diabetes

These medications also increase the uptake of glucose by muscle tissue, decrease glucose release by the liver, and increase satiety at the level of the hypothalamus

Routine monitoring of renal function and electrolytes is essential in this population

Comparison With Prior Work The integration of supported self-care interventions involving pharmacotherapy into obesity management represents a major shift that can help address the various challenges associated with weight loss and maintenance